{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:29:06Z","timestamp":1778570946472,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T00:00:00Z","timestamp":1619049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-106-2314-B-002-075-MY3"],"award-info":[{"award-number":["MOST-106-2314-B-002-075-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST-106-2314-B-002-075"],"award-info":[{"award-number":["MOST-106-2314-B-002-075"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH-105-S3046"],"award-info":[{"award-number":["NTUH-105-S3046"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s12072-021-10186-7","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T08:05:46Z","timestamp":1619078746000},"page":"582-592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients"],"prefix":"10.1007","volume":"15","author":[{"given":"Huei-Ru","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Chih","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Ru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ta-Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"You-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung-Hung","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tai-Chung","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-7952","authenticated-orcid":false,"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,22]]},"reference":[{"key":"10186_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386:1546\u20131555","journal-title":"Lancet"},{"key":"10186_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11901-016-0304-z","volume":"15","author":"HC Yang","year":"2016","unstructured":"Yang HC, Kao JH. Revisiting the natural history of chronic HBV infection. Curr Hepatol Rep 2016;15:141\u2013149","journal-title":"Curr Hepatol Rep"},{"key":"10186_CR3","doi-asserted-by":"publisher","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","volume":"4","author":"MF Yuen","year":"2018","unstructured":"Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers 2018;4:18035","journal-title":"Nat Rev Dis Primers"},{"key":"10186_CR4","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.jfma.2018.08.020","volume":"117","author":"JH Kao","year":"2018","unstructured":"Kao JH. Hepatitis B: from control to cure. J Formos Med Assoc 2018;117:868\u2013870","journal-title":"J Formos Med Assoc"},{"key":"10186_CR5","unstructured":"Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019"},{"key":"10186_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","volume":"10","author":"SK Sarin","year":"2016","unstructured":"Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hep Int 2016;10:1\u201398","journal-title":"Hep Intl"},{"issue":"67","key":"10186_CR7","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017;2017(67):370\u2013398","journal-title":"J Hepatol"},{"key":"10186_CR8","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67:1560\u20131599","journal-title":"Hepatology"},{"key":"10186_CR9","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/hep.28438","volume":"63","author":"G Papatheodoridis","year":"2016","unstructured":"Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology 2016;63:1481\u20131492","journal-title":"Hepatology"},{"key":"10186_CR10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12072-019-09989-6","volume":"13","author":"YF Liaw","year":"2019","unstructured":"Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hep Int 2019;13:665\u2013673","journal-title":"Hep Intl"},{"key":"10186_CR11","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.26549","volume":"58","author":"WJ Jeng","year":"2013","unstructured":"Jeng WJ, Sheen IS, Chen YC, et al. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888\u20131896","journal-title":"Hepatology"},{"key":"10186_CR12","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/gutjnl-2014-307237","volume":"64","author":"WK Seto","year":"2015","unstructured":"Seto WK, Hui AJ, Wong VW, et al. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2015;64:667\u2013672","journal-title":"Gut"},{"key":"10186_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/infdis\/jix690","volume":"217","author":"TH Su","year":"2018","unstructured":"Su TH, Yang HC, Tseng TC, et al. Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy. J Infect Dis 2018;217:1193\u20131201","journal-title":"J Infect Dis"},{"key":"10186_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","volume":"61","author":"CH Chen","year":"2014","unstructured":"Chen CH, Lu SN, Hung CH, et al. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol. 2014;61:515\u201322.","journal-title":"J Hepatol"},{"key":"10186_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/ajg.2016.109","volume":"111","author":"CC Wang","year":"2016","unstructured":"Wang CC, Tseng KC, Hsieh TY, et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg. Am J Gastroenterol 2016;111:1286\u20131294","journal-title":"Am J Gastroenterol"},{"key":"10186_CR16","doi-asserted-by":"crossref","unstructured":"Carey I, Gersch J, Wang B, et al. Pre-genomic HBV RNA and HBcrAg predict outcomes in HBeAg negative chronic hepatitis B patients suppressed on nucleos(t)ide analogue therapy. Hepatology 2019","DOI":"10.1002\/hep.31026"},{"key":"10186_CR17","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/apt.15058","volume":"49","author":"YC Hsu","year":"2019","unstructured":"Hsu YC, Nguyen MH, Mo LR, et al. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107\u201315.","journal-title":"Aliment Pharmacol Ther"},{"issue":"719\u201327","key":"10186_CR18","first-page":"e7","volume":"18","author":"R Fan","year":"2020","unstructured":"Fan R, Zhou B, Xu M, et al. Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy. Clin Gastroenterol Hepatol 2020;18(719\u201327):e7","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10186_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.antiviral.2020.104992","volume":"185","author":"ILP Tout","year":"2021","unstructured":"Tout ILP, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antivir Res 2021; 185: 92","journal-title":"Antivir Res"},{"key":"10186_CR20","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.virol.2015.02.031","volume":"479\u2013480","author":"C Seeger","year":"2015","unstructured":"Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479\u2013480:672\u201386.","journal-title":"Virology"},{"key":"10186_CR21","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3748\/wjg.v19.i41.6995","volume":"19","author":"F Rodriguez-Frias","year":"2013","unstructured":"Rodriguez-Frias F, Buti M, Tabernero D, et al. Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. World J Gastroenterol WJG 2013;19:6995\u20137023","journal-title":"World J Gastroenterol WJG"},{"key":"10186_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1053\/j.gastro.2018.07.058","volume":"156","author":"AL McNaughton","year":"2019","unstructured":"McNaughton AL, D\u2019Arienzo V, Ansari MA, et al. Insights from deep sequencing of the HBV genome-unique, tiny, and misunderstood. Gastroenterology 2019;156:384\u2013399","journal-title":"Gastroenterology"},{"key":"10186_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1053\/j.gastro.2007.06.011","volume":"133","author":"SG Lim","year":"2007","unstructured":"Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion. Gastroenterology 2007;133:951\u2013958","journal-title":"Gastroenterology"},{"key":"10186_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jhep.2010.06.018","volume":"54","author":"S Wu","year":"2011","unstructured":"Wu S, Imazeki F, Kurbanov F, et al. Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion. J Hepatol 2011;54:19\u201325","journal-title":"J Hepatol"},{"key":"10186_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2012.09.017","volume":"58","author":"Y Cheng","year":"2013","unstructured":"Cheng Y, Guindon S, Rodrigo A, et al. Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. J Hepatol 2013;58:217\u2013224","journal-title":"J Hepatol"},{"key":"10186_CR26","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1136\/gutjnl-2012-302408","volume":"62","author":"Y Cheng","year":"2013","unstructured":"Cheng Y, Guindon S, Rodrigo A, et al. Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. Gut 2013;62:1347\u20131355","journal-title":"Gut"},{"key":"10186_CR27","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1007\/s11262-019-01689-5","volume":"55","author":"N Chuaypen","year":"2019","unstructured":"Chuaypen N, Payungporn S, Poovorawan K, et al. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Virus Genes 2019;55:610\u2013618","journal-title":"Virus Genes"},{"key":"10186_CR28","doi-asserted-by":"publisher","first-page":"17950","DOI":"10.1038\/srep17950","volume":"5","author":"L Yan","year":"2015","unstructured":"Yan L, Zhang H, Ma H, et al. Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg-positive chronic hepatitis B patients. Sci Rep 2015;5:17950","journal-title":"Sci Rep"},{"key":"10186_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.genom.9.081307.164359","volume":"9","author":"ER Mardis","year":"2008","unstructured":"Mardis ER. Next-generation DNA sequencing methods. Annu Rev Genom Hum Genet 2008;9:387\u2013402","journal-title":"Annu Rev Genom Hum Genet"},{"key":"10186_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2004.06.031","volume":"41","author":"SH Yeh","year":"2004","unstructured":"Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004;41:659\u2013666","journal-title":"J Hepatol"},{"key":"10186_CR31","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/liv.13346","volume":"37","author":"DK Wong","year":"2017","unstructured":"Wong DK, Seto WK, Cheung KS, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int 2017;37:995\u20131001","journal-title":"Liver Int"},{"issue":"1518\u201329","key":"10186_CR32","first-page":"e3","volume":"157","author":"TC Tseng","year":"2019","unstructured":"Tseng TC, Liu CJ, Hsu CY, et al. High level of hepatitis B Core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic hbv infection of intermediate viral load. Gastroenterology 2019;157(1518\u201329):e3","journal-title":"Gastroenterology"},{"key":"10186_CR33","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/nar\/11.6.1747","volume":"11","author":"Y Ono","year":"1983","unstructured":"Ono Y, Onda H, Sasada R, et al. The complete nucleotide sequences of the cloned hepatitis B virus DNA; subtype adr and adw. Nucleic Acids Res 1983;11:1747\u20131757","journal-title":"Nucleic Acids Res"},{"key":"10186_CR34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.virol.2016.03.017","volume":"493","author":"J Gregori","year":"2016","unstructured":"Gregori J, Perales C, Rodriguez-Frias F, et al. Viral quasispecies complexity measures. Virology 2016;493:227\u2013237","journal-title":"Virology"},{"key":"10186_CR35","doi-asserted-by":"publisher","first-page":"e70169","DOI":"10.1371\/journal.pone.0070169","volume":"8","author":"CJ Huang","year":"2013","unstructured":"Huang CJ, Wu CF, Lan CY, et al. Impact of genetic heterogeneity in polymerase of hepatitis B virus on dynamics of viral load and hepatitis B progression. PLoS One 2013;8:e70169","journal-title":"PLoS One"},{"key":"10186_CR36","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1128\/JVI.02164-09","volume":"84","author":"HY Wang","year":"2010","unstructured":"Wang HY, Chien MH, Huang HP, et al. Distinct hepatitis B virus dynamics in the immunotolerant and early immunoclearance phases. J Virol 2010;84:3454\u20133463","journal-title":"J Virol"},{"key":"10186_CR37","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5009\/gnl18425","volume":"13","author":"LY Mak","year":"2019","unstructured":"Mak LY, Seto WK, Fung J, et al. New biomarkers of chronic hepatitis B. Gut Liver 2019;13:589\u2013595","journal-title":"Gut Liver"},{"key":"10186_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/cells9020493","volume":"9","author":"M Papatheodoridi","year":"2020","unstructured":"Papatheodoridi M, Papatheodoridis G. Emerging diagnostic tools to decide when to discontinue nucleos(t)ide analogues in chronic hepatitis B. Cells. 2020;9:493.","journal-title":"Cells"},{"key":"10186_CR39","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1172\/JCI3731","volume":"102","author":"C Boni","year":"1998","unstructured":"Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Investig 1998;102:968\u2013975","journal-title":"J Clin Investig"},{"issue":"963\u201373","key":"10186_CR40","first-page":"e9","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni C, Laccabue D, Lampertico P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143(963\u201373):e9","journal-title":"Gastroenterology"},{"key":"10186_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cmi.2015.10.007","volume":"22","author":"L Chen","year":"2016","unstructured":"Chen L, Gan QR, Zhang DQ, et al. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:201\u2013207","journal-title":"Clin Microbiol Infect"},{"key":"10186_CR42","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1172\/JCI92812","volume":"128","author":"L Rivino","year":"2018","unstructured":"Rivino L, Le Bert N, Gill US, et al. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. J Clin Investig 2018;128:668\u2013681","journal-title":"J Clin Investig"},{"issue":"3","key":"10186_CR43","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.jhepr.2021.100254","volume":"3","author":"S-R Lin","year":"2021","unstructured":"Lin S-R, Yang T-Y, Peng C-Y, Lin Y-Y, Dai C-Y, Wang H-Y, Su T-H, Tseng T-C, Liu I-J, Cheng H-R, Shen Y-C, Wu F-Y, Liu C-J, Chen D-S, Chen P-J, Yang H-C, Kao J-H. Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. JHEP Reports. 2021;3(3):100254.","journal-title":"JHEP Reports"}],"updated-by":[{"DOI":"10.1007\/s12072-021-10245-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,9,25]],"date-time":"2021-09-25T00:00:00Z","timestamp":1632528000000}}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10186-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T16:23:55Z","timestamp":1633105435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10186-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,22]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10186"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10186-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12072-021-10245-z","asserted-by":"object"}]},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,22]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12072-021-10245-z","URL":"https:\/\/doi.org\/10.1007\/s12072-021-10245-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HRC, H-CY, SRL, T-YY, Y-YL, T-HS, T-CT, C-JL, J-HK declare no competing interests related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected by a priori approval by the Institutional Review Board of the National Taiwan University Hospital. All patients gave their written informed consents at enrollment.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate (Ethics)"}},{"value":"Yes<b>.<\/b>","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish (Ethics)"}}]}}